Dr. Sascha Karassek

• Team lead of 8 people (scientist and lab analysts) • Initiation and control of GMP conform execution of bioassays for biologics for lot release and stability samples • Processing of OOS/OOT results, deviation and CAPAs • Method transfer & Bioassay validation according to ICH / USP guidelines • SOP and GMP relevant document preparation • Assay price calculation and assistance of quote generation • Process optimization • Report to internal and external stakeholders

• Initiation and control of GMP conform execution of bioassays for biologics (proliferation-, cytotoxicity-, luciferase reporter-, FACS binding assays) for lot release and stability samples • Processing of OOS/OOT results, deviation and CAPAs • Method transfer & Bioassay validation according to ICH / USP guidelines • SOP and GMP relevant document preparation • Assay price calculation and assistance of quote generation • Process optimization • Report to internal and external stakeholders

•Team lead preclinical drug target and biomarker validation studies in the field of (immuno-) oncology using a wide range of cell based assays, protein biochemical assays and molecular biology. •Project management: - Experimental design - Write and optimize assay protocols - Data analysis and presentation / discussion with customer •Platform development for in vivo CRISPR/Cas9 screening to identify I/O targets and in vitro CRISPR/Cas9 base editing applications •BD meetings with potential new clients

Molekulare und zellbiologische Untersuchung des Bordetella pertussis VIrulenzfaktors (Pertussis Toxin) auf die Blut-Hirn-Schranke. (Karassek et al. (J Biol Chem. 2015 Oct 9;290(41):24835-43.), Starost et al. (Toxins (Basel). 2016 Oct 13;8(10).)

Planung, Koordinierung und Durchführung von Projekten innerhalb des SFB 642, Teilprojekt A6. Anleitung von wissenschaftlichem Personal und Betreuung von Studenten im Rahmen von Bachelor- und Masterarbeiten.

molekularbiologische, zellbiologische und proteinbiochemische Arbeiten im onkologischen und neurodegenerativen Umfeld zur Aufklärung von apoptotischen Signalmechanismen. (Karassek et al. (J Biol Chem. 2010 Oct 29;285(44):33979-91.))

molekulare Onkologie, molekulare Medizin, single-chain-Antikörper